DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES

the specification of wh	ich:		
/_/is attached hereto	o.		·
/X/ was filed on No box contains an X //			o. <u>08/974,565</u> and if this
	box contains an X /_/,	was amended on under	No on Patent Cooperation Treaty nded on
I hereby state the specification, including			ts of the above-identified eferred to above.
I acknowledge application in accordan			erial to the examination of this s, §1.56(a).
foreign application(s) f Cooperation Treaty into United States indicated inventor's certificate an	or patent or inventor's or ernational applications below and have also in d Patent Cooperation 1 the United States for the	certificate indicated being (s) designating at least dentified below any for freaty international appare same subject matter	one country other than the reign application(s) for patent or plication(s) designating at least and having a filing date before
Country	Number	Filing Date // Yes // Yes	/_/ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application		Status (Pending,
Serial No.	Filed	Abandoned, Patented)
08/624,663	March 25, 1996	Pending

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749 Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ. INCYTE PHARMACEUTICALS, INC. 3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555 FAX: 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Sole Inventor or First Joint Inventor:

Full name:

JANICE AU-YOUNG

Signature:

Date:

March 3 . 1998

Citizenship:

United States of America

Residence:

Berkeley, California

P.O. Address:

1419 Kains Avenue

Berkeley, California, 94702

Second Joint Inventor:

Full name:

BENJAMIN G. COCKS

Signature:

Date:

11

Citizenship:

Australia

Residence:

Palo Alto, California

P.O. Address:

4292 D Wilke Way

Palo Alto, California 94306

Third Joint Inventor:

Full name:

ROGER COLEMAN

Signature:

Feb 22

1998

Citizenship:

Date:

United States of America

Residence:

Mountain View, California

P.O. Address:

260 Mariposa Street, #2

Mountain View, California, 94041

Fourth Joint Inventor:

Full name:

JEFFREY J. SEILHAMER

Signature:

Date:

Feb 23

. 1998

Citizenship:

United States of America

Residence:

Los Altos Hills, California

P.O. Address:

12555 La Cresta

Los Altos Hills, California, 94022

Fifth Joint Inventor:

Full name:

DOUGLAS A. FISHER

Signature:

Date:

26 1998

Citizenship:

United States of America

Residence:

Groton, Connecticut

P.O. Address:

600 Meridian Street, #824

Groton, Connecticut 06340

Docket No.: PF-0057-4 CON

Certificate of Mailing

"Express Mail" mailing label number 330 963 920 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on <u>July 25, 2003</u>.

By: Ac	ene !	izu	Printed:	Diane Kizer	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Au-Young et al.

Title:

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9718, Frame 0495, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749	Michelle M. Stempien	Reg. No. 41,327
Jenny Buchbinder	Reg. No. 48,588	David G. Streeter	Reg. No. 43,168
Diana Hamlet-Cox	Reg. No. 33,302	James M. Verna	Reg. No. 33,287
Joel Harris	Reg. No. 44,743	Yu-Mei Eureka Wang	Reg. No. 50,510
Richard C. Ekstrom	Reg. No. 37,027	Shirley A. Recipon	Reg. No. 47,016
Barrie D. Greene	Reg. No. 46,740	Cathleen M. Rocco	Reg. No. 46,172
Lori L. Kerber	Reg. No. 41,113	Susan K. Sather	Reg. No. 44,316
Gina C. Nellesen	Reg. No. 52,062		- '

112596

Docket No.: PF-0057-4 CON

Please direct all correspondence to:

Legal Department
Incyte Corporation
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Corporation, Phone: (650) 845-4639, Fax: (650) 849-8886 or (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE CORPORATION

Date: _	July 25, 2003	By: / Whileher
		Lee Bendekgey
		EVP General Counsel/Corporate Secretary



D partment of Energy

Washington, DC 20585

MAR 3 2003

Mr. Michael Carone
Office of Licensing and Review
U.S. Patent and Trademark Office
Technology Group 3600
Crystal Park 5
Arlington, Virginia

Re:

Blanket Exemption from Requirements Under §42 U.S.C. 2182 for Incyte

Genomics, Inc.

Dear Mr. Carone:

The U.S. Department of Energy (DOE) wished to grant Incyte Genomics, Inc. (Incyte) a blanket exemption form the requirements under §42 U.S.C. 2182 for their patent applications disclosing inventions involving radionuclides. This blanket exemption is granted based on assertions set forth in Incyte's letter to DOE dated February 25, 2003. No blanket exemption is granted from the requirements of any other statute, including the security review statute, §42 U.S.C. 2181.

This blanket exemption will be effective from the date of this letter for one (1) calendar year (the "Blanket Exemption Period"), and covers all Incyte patent applications now pending before the U.S. Patent and Trademark Office and will cover all Incyte patent applications filed within the Blanket Exemption Period. Therefore, the Blanket Exemption Period ends on February 26, 2004. For the Blanket Exemption Period, Incyte will include a copy of this letter with all applicable applications. This blanket exemption may be renewed for successive one (1) year periods upon Incyte's request, subject to DOE approval. DOE will notify your office in writing of such renewals, if granted.

Sincerely,

Paul A. Gottlieb

Assistant General Counsel for Technology Transfer and Intellectual Property

(202) 586-2802